NCT04898348View on ClinicalTrials.gov

A Study to Investigate Efficacy and Safety of KBL697 in Patients With Mild to Moderate Active Ulcerative Colitis

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 14, 2022

Primary Completion Date

July 28, 2023

Study Completion Date

July 28, 2023

Conditions
Ulcerative Colitis
Interventions
DRUG

KBL697

3 capsules twice a day dosing of KBL697

DRUG

Placebo

3 capsules twice a day dosing of Placebo

Trial Locations (1)

3002

The Royal Melbourne Hospital, Melbourne

Sponsors

Lead Sponsor

KoBioLabs
All Listed Sponsors
lead

KoBioLabs

INDUSTRY

NCT04898348 - A Study to Investigate Efficacy and Safety of KBL697 in Patients With Mild to Moderate Active Ulcerative Colitis | Biotech Hunter | Biotech Hunter